This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
CardioSTAT has now become the leading wearable cardiac monitoring solution in Canada. It is committed to improving cardiac monitoring and accessibility for both patients and physicians, by offering leading edge solutions to major problems in the field of medical testing. See Full Press Release at the Source: Icentia Receives U.S.
WHO confirmed that the newly approved WLAs include: The European Medicines Regulatory Network (EMRN), which is made up of the European Commission (EC), the European Medicines Agency (EMA) and the medicines regulatory authorities of 30 countries.
When building provider networks, it is crucial to include providers who can assess and address social determinants to ensure that care is equitable, patient-centered, and effective in improving health outcomes and reducing healthcare disparities. Cost Savings: Addressing SDoH can lead to cost savings in the long run.
billion, leading to $13.6 The study found that if certain adults received medically-tailored meals, about 1.6 million hospitalizations would have been avoided, resulting in $38.7 billion saved in healthcare expenditures. Programs to provide these meals would have cost $24.8 billion in net savings, according to the report.
According to the findings, nearly 90 percent of US biotechs rely on imported components for at least half of their products approved by the US Food and Drug Administration. This makes supply of medicines vulnerable especially to proposed tariffs on the EU, China, and Canada, according to BIO.
Strict guidelines from the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) require marketers to ensure transparency and accuracy in all communications. Organizations like Pharma Marketing Network offer in-depth articles that help marketers tailor their strategies to real patient needs.
The alliance will focus on measures to expedite the clinical programme of NKGen using its autologous NK cell therapy, SNK01, and leveraging its clinical partners and donors’ network. Based in the US, NKGen develops and markets new autologous, allogeneic and CAR-NK NK cell therapies.
The clinic will develop pre-clinical studies into early and late phase clinical trials to identify US Food and Drug Administration (FDA)-approved advanced regenerative medicines. The Cedars-Sinai Board of Governors Regenerative Medicine Institute and the Smidt Heart Institute will lead the project. Scientific and operational teams.
Also, if you’re reading this episode, whether you’re trying to break in, already or a medical sales professional, or you’re leading the way, you’re going to learn something that you probably haven’t heard before. I then got a chance to lead at the director level. — Sam, how are you doing?
The DDiCT project will be co-led by Bristol Myers Squibb (BMS)’s Disability Advancement Workplace Network (DAWN) and the Global Drug Development Team. Therefore, it is essential that we broaden the scope of medical trials and research,” commented Tinamarie Duff, DAWN Global People & Business Resource Group Lead.
the leading provider of convenient, clinical-grade blood collection solutions, announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+ lancet as a Class II medical device. Tasso, Inc., For more information on the Tasso+ device-based solutions with Class II clearance, please visit www.tassoinc.com/contact.
where she leads the company’s clinical education and advancement strategies. In this podcast, I interview top medical sales reps and leading medical sales executives across the entire world. So I’m an introvert, so networking can sometimes be a struggle for me. It was the drive, it was the, it was the desire.
Food & Drug Administration (FDA) for its smaller-diameter CurvaFix® IM Implant indicated for fixation of fractures of the pelvis. Often, conservative treatment leads to lengthy hospitalizations, high nursing home admittance, and a high one-year mortality rate. Food & Drug Administration (FDA). CurvaFix, Inc.,
Food and Drug Administration (FDA) 510(k) clearance for DiLumen EZ¹, a single-use, disposable endotherapy device for endoscopic mucosal resections (EMR) and difficult colonoscopies. Connecticut-based medical device innovator Lumendi, LLC announced that it has received U.S.
The Food and Drug Administration (FDA) plays a critical role in regulating the pharmaceutical industry and ensuring that medications and medical devices marketed to the public are safe, effective, and appropriately labeled. appeared first on Pharma Marketing Network. The post Why Is FDA Issuing Fewer Marketing Violation Letters?
Activ Surgical is on the leading edge when it comes to enhancing surgical vision and significantly reducing unintended medical errors, and I am confident that ActivSight will improve surgical outcomes.”. Activ Surgical received 501(k)-clearance for ActivSight by the Food and Drug Administration (FDA) in the United States in 2021.
Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System. The EndoStim System consists of an implantable neurostimulation device and lead placed via a quick, minimally-invasive laparoscopic procedure. About the EndoStim System.
Utilizing the Halo cloud-based platform allowed HeartBeam to meet its schedule for FDA submission of the HeartBeam AIMI software for acute care settings that provides a 3D vector electrogram (VECG) comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack.
MicroPort Navibot has received 510(K) clearance from the Food and Drug Administration (FDA) in the United States for the SkyWalker System, the company’s first robot-assisted platform for orthopedic applications. Our clients include both blue-chip companies and innovative startups within the MedTech space.
Neoadjuvant nivolumab did not lead to surgical delays. Neoadjuvant nivolumab in combination with chemotherapy was approved by the US Food and Drug Administration (FDA) in March 2022 for lung cancer. “Although the sample size was small, the results illustrate the potential power of pathological response as a predictive biomarker.”
HemoSonics, LLC , a leading medical device company delivering individualized diagnostic solutions for Patient Blood Management (PBM), announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the Quantra Hemostasis System with QStat Cartridge.
Food and Drug Administration for commercial use in the United States. Trauma/ER: The BodyTom 64’s unique combination of internal lead shielding and battery operation allows any standard trauma bay to be transformed into an advanced CT imaging suite. For more information, please visit: www.NeuroLogica.com.
Tyber Medical LLC, the global, leading private-label medical device provider for major orthopedic trauma, extremity, and spine companies, has been awarded a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new NiTy+ One-Shot Staple Fixation System.
It represents one of the largest-ever global private-sector investments in the country and strengthens the company’s Europe-wide production network. At Sandoz, we are determined to continue leading the way in driving access to these critical medicines.
These developments, together with Walgreens’ recent rollout of Health Corners that help patients manage chronic conditions and its October 2022 announcement that it would fully acquire CareCentrix (a platform that coordinates post-acute and home care), underscore Walgreens’ plans to become a leading healthcare provider.
Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to advance the company’s PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and effectiveness of the Vivasure PerQseal ® Closure Device System. For more information, please visit www.vivasuremedical.com.
Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system. The Axonics R20 neurostimulator utilizes the same small 5cc form factor as the Axonics R15 and is paired with the same tined lead and intuitive patient remote control. Axonics, Inc.,
Food and Drug Administration (FDA). ChroniSense Medical, a portfolio company of Rainbow Medical, is continuing its clinical development in collaboration with leading hospitals, partners, and expert practitioners in the U.S., ChroniSense Medical Ltd. “With 6 out of 10 adults in the US living with a chronic condition, and over $1.1
Food and Drug Administration (FDA) 510(k) clearance and launch of the company’s upgraded AI-powered software. We are committed to continuous improvement to optimize the clinical utility of the Swoop® system while driving commercial adoption across leading institutions globally. Hyperfine, Inc., The Swoop® system received initial U.S.
Food and Drug Administration (FDA) for 510(k) clearance. The ALICE device is being contract manufactured by an end-to-end solution provider that offers New Product Introduction (NPI) services to mass production capabilities for leading medical electronic device companies. and Israel.
For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market.
A recent report from the US Food and Drug Administration (FDA) shows that while the number of new drug shortages has fallen significantly from a high of 250 in 2011 to 49 in 2022, there was an increase in new drug shortages year-on-year. Going forward, it is imperative for companies to invest in constructing more resilient supply networks.
Given that less than 10% of rare diseases currently have an available treatment approved by the United States Food and Drug Administration (FDA) , advocating for the speedy development of novel drugs and therapies is a crucial step in improving the quality of life for those affected. What is a Rare Disease?
Food and Drug Administration (FDA) has granted the coveted Breakthrough Device Designation for its LifeGel Absorbable Surgical Hemostat. Medcura, Inc., a medical device company dedicated to transformatively improving the management of surgical bleeding, announces that the U.S.
Food & Drug Administration’s proposed Computer System Assurance (CSA) guidelines, the old methods of unit tests and standardized manual and automated testing are no longer adequate for ensuring both solution security and healthcare outcomes. According to the U.S.
Creating a layman’s lexicon that speaks to patients plainly, directly, and clearly will bridge the “gap of understanding” between HCP and patient, leading to quicker diagnosis and treatment decisions. The post Understanding and Adapting to the New Patient Journey appeared first on Pharma Marketing Network.
Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments (ED) each year. 1 The risk of death from sepsis increases by as much as 8 percent each hour the condition goes untreated.
Energy crisis effects will be felt across healthcare, but for medicines manufacturing and delivery the issue is especially complex because the networks of medicine supply extend across the globe and across countries which see differing impacts of energy costs and supply. Medicines manufacturing is energy intensive.
Regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) place great importance on data integrity in the pharmaceutical/life science industry. Blockchain technology creates a decentralised and unalterable ledger that records all transactions across a network of computers.
Compared to the aforementioned copper‑based radionuclides, Cu-64 has a longer production and decay time, which leads to a more expensive production process and a higher radiation burden for the patient. During her career, she held positions of increasing responsibility to lead companies in the field, including AREVA/Framatome.
Food and Drug Administration (FDA) 510(k) clearance for DiLumen EZ¹, a single-use, disposable endotherapy device intended for endoscopic mucosal resections (EMR) and difficult colonoscopies. Lumendi, LLC has announced it has filed for U.S. Simultaneously, Lumendi has filed for U.S.
Food and Drug Administration (FDA) granted marketing authorization of the MISHA Knee System, an implantable shock absorber (ISA) for the knee. Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation.
1 The regulation is the culmination of a long debate between European Union (EU) Member States and health sector stakeholders, triggered by joint actions such as European Network for Health Technology Assessment (EUnetHTA) and formalised through the European Commission (EC)’s proposal in January 2018. effectiveness and therapeutic efficacy.
Before marketing the device, a pre-market submission and approval are required by Food and Drug Administration FDA. That may frequently lead your team to race to complete all necessary tasks before the product’s debut. Begin Preparation Before FDA Approval. Employee training is a critical component of any launch strategy.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content